Chicago Equity Partners LLC increased its position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 80.9% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 213,680 shares of the biotechnology company’s stock after purchasing an additional 95,545 shares during the period. Chicago Equity Partners LLC’s holdings in Ironwood Pharmaceuticals were worth $3,203,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Gerber Kawasaki Wealth & Investment Management purchased a new stake in shares of Ironwood Pharmaceuticals in the third quarter worth about $170,000. Ameritas Investment Partners Inc. lifted its position in shares of Ironwood Pharmaceuticals by 5.8% in the second quarter. Ameritas Investment Partners Inc. now owns 11,821 shares of the biotechnology company’s stock worth $223,000 after buying an additional 648 shares in the last quarter. Virtu KCG Holdings LLC lifted its position in shares of Ironwood Pharmaceuticals by 10.3% in the second quarter. Virtu KCG Holdings LLC now owns 15,740 shares of the biotechnology company’s stock worth $297,000 after buying an additional 1,470 shares in the last quarter. Amalgamated Bank lifted its position in shares of Ironwood Pharmaceuticals by 9.0% in the second quarter. Amalgamated Bank now owns 17,280 shares of the biotechnology company’s stock worth $326,000 after buying an additional 1,421 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. lifted its position in shares of Ironwood Pharmaceuticals by 30.9% in the third quarter. Oppenheimer Asset Management Inc. now owns 23,405 shares of the biotechnology company’s stock worth $369,000 after buying an additional 5,527 shares in the last quarter.

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) opened at $13.57 on Monday. The company has a debt-to-equity ratio of -22.31, a quick ratio of 4.86 and a current ratio of 4.87. Ironwood Pharmaceuticals, Inc. has a 52 week low of $13.56 and a 52 week high of $19.94. The firm has a market capitalization of $2,030.00, a P/E ratio of -14.14 and a beta of 1.28.

In other Ironwood Pharmaceuticals news, insider Mark G. Currie sold 60,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 24th. The stock was sold at an average price of $15.45, for a total transaction of $927,000.00. Following the sale, the insider now directly owns 835,000 shares of the company’s stock, valued at $12,900,750. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Peter M. Hecht sold 113,405 shares of the business’s stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $15.12, for a total value of $1,714,683.60. Following the sale, the chief executive officer now directly owns 4,696,917 shares in the company, valued at $71,017,385.04. The disclosure for this sale can be found here. Insiders have sold 175,769 shares of company stock worth $2,679,491 over the last three months. 7.63% of the stock is currently owned by insiders.

A number of equities research analysts recently commented on IRWD shares. ValuEngine upgraded Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, November 29th. BidaskClub downgraded Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, December 30th. Morgan Stanley reiterated a “hold” rating on shares of Ironwood Pharmaceuticals in a research report on Monday, December 4th. Bank of America downgraded Ironwood Pharmaceuticals from a “buy” rating to an “underperform” rating and decreased their target price for the stock from $20.00 to $15.00 in a research report on Friday, January 5th. Finally, Zacks Investment Research upgraded Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, January 18th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $17.56.

WARNING: “Ironwood Pharmaceuticals, Inc. (IRWD) Shares Bought by Chicago Equity Partners LLC” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2018/02/05/ironwood-pharmaceuticals-inc-irwd-shares-bought-by-chicago-equity-partners-llc.html.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.

Want to see what other hedge funds are holding IRWD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD).

Institutional Ownership by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.